MediBeacon Inc. Appoints Dr. Steve Miller as Chief Medical Officer
MediBeacon expands management team as enrollment in Phase 3 study focused on kidney disease is completed ST. LOUIS, May 16, 2023 /PRNewswire/ -- MediBeacon Inc., a portfolio company within the Pansend Life Sciences segment of INNOVATE Corp. (NYSE: VATE), today announced the appointment of Dr.Ste...
MediBeacon Receives $10 Million in Amended Agreements with Huadong Medicine to Accelerate Development of Transdermal GFR Measurement System
MediBeacon approaching completion of Phase 3 study focused on kidney disease; Has submitted three of five required PMA modules needed for FDA approval ST. LOUIS, Nov. 16, 2022 /PRNewswire/ -- MediBeacon Inc., a portfolio company within the Pansend Life Sciences segment of INNOVATE Corp. (NYSE: VA...